Senate Appropriators Urge FDA To Use Enforcement Discretion For CBD

By Beth Wang / August 9, 2021 at 5:27 PM
Senate appropriators want FDA to exercise enforcement discretion for products containing hemp-derived cannabidiol. In their fiscal 2022 funding report released last week, the lawmakers ask FDA to issue a policy of enforcement discretion and maintain that stance until it establishes a process for product sponsors to notify the agency that their products contain CBD and to share safety data about those products. The lawmakers give FDA 90 days from the date the fiscal 2022 appropriations bill is enacted to issue...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.